PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18512759-8	2008	This effect of NAC was blocked by the Cdk5 inhibitors roscovitine and butyrolactone.	4-Butyrolactone	70-83	cyclin dependent kinase 5	Homo sapiens	38-42	
32054125-2	2020	During the phenotypic screening of secondary metabolites derived from the marine fungus Aspergillus terreus, a poly cyclin-dependent kinase (CDK) inhibitor butyrolactone I affecting CDK1 and CDK5 was discovered as a potent adiponectin production-enhancing compound in the adipogenesis model of human bone marrow-derived mesenchymal stem cells (hBM-MSCs).	4-Butyrolactone	156-169	cyclin dependent kinase 5	Homo sapiens	141-144	
32054125-2	2020	During the phenotypic screening of secondary metabolites derived from the marine fungus Aspergillus terreus, a poly cyclin-dependent kinase (CDK) inhibitor butyrolactone I affecting CDK1 and CDK5 was discovered as a potent adiponectin production-enhancing compound in the adipogenesis model of human bone marrow-derived mesenchymal stem cells (hBM-MSCs).	4-Butyrolactone	156-169	cyclin dependent kinase 5	Homo sapiens	191-195	
15369765-4	2004	The ROCK inhibitor Y-27632 significantly increased Csp24 phosphorylation, and the Rho activator lysophosphatidic acid (LPA) or the Cdk5 inhibitor butyrolactone significantly decreased Csp24 phosphorylation.	4-Butyrolactone	146-159	cyclin dependent kinase 5	Homo sapiens	131-135	
10544291-6	1999	The Ser75 phosphorylation was inhibited in a dose-dependent manner by butyrolactone I, a specific inhibitor of Cdk5-type kinases.	4-Butyrolactone	70-83	cyclin dependent kinase 5	Homo sapiens	111-115	
11978846-4	2002	This upregulation is accompanied by increased Cdk5 kinase activity, which is blocked completely by the Cdk5 inhibitor butyrolactone I. Microinjection of butyrolactone I into the lateral septum and hippocampus prevents the acquisition of conditioned context-dependent fear as well as its stress-induced facilitation.	4-Butyrolactone	118-131	cyclin dependent kinase 5	Homo sapiens	46-50	
11978846-4	2002	This upregulation is accompanied by increased Cdk5 kinase activity, which is blocked completely by the Cdk5 inhibitor butyrolactone I. Microinjection of butyrolactone I into the lateral septum and hippocampus prevents the acquisition of conditioned context-dependent fear as well as its stress-induced facilitation.	4-Butyrolactone	118-131	cyclin dependent kinase 5	Homo sapiens	103-107	
11978846-4	2002	This upregulation is accompanied by increased Cdk5 kinase activity, which is blocked completely by the Cdk5 inhibitor butyrolactone I. Microinjection of butyrolactone I into the lateral septum and hippocampus prevents the acquisition of conditioned context-dependent fear as well as its stress-induced facilitation.	4-Butyrolactone	153-166	cyclin dependent kinase 5	Homo sapiens	46-50	
11978846-4	2002	This upregulation is accompanied by increased Cdk5 kinase activity, which is blocked completely by the Cdk5 inhibitor butyrolactone I. Microinjection of butyrolactone I into the lateral septum and hippocampus prevents the acquisition of conditioned context-dependent fear as well as its stress-induced facilitation.	4-Butyrolactone	153-166	cyclin dependent kinase 5	Homo sapiens	103-107	
15051507-8	2004	Further confirmation of cdk5 involvement in this process was based on the findings that inhibition of the kinase activity with butyrolactone-I prevents the appearance of tau of Alzheimer type in IL-6-treated neurons.	4-Butyrolactone	127-140	cyclin dependent kinase 5	Homo sapiens	24-28